Inhibrx Biosciences (INBX) Non-Current Assets (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Non-Current Assets for 3 consecutive years, with $13.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Assets fell 33.01% year-over-year to $13.6 million; the TTM figure through Dec 2025 stood at $67.1 million (up 4.22% YoY), while the FY2025 annual figure was $13.6 million, down 33.01% from the prior year.
• Non-Current Assets eased to $13.6 million in Q4 2025 per INBX's latest filing, from $16.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $20.4 million in Q4 2024 and bottomed at $12.5 million in Q4 2023.
• Historically, Non-Current Assets has averaged $16.4 million across 3 years, with a median of $16.2 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Assets jumped 62.5% — and 2025, when it tumbled 33.01%.
• Inhibrx Biosciences' Non-Current Assets stood at $12.5 million in 2023, then jumped by 62.5% to $20.4 million in 2024, then sank by 33.01% to $13.6 million in 2025.
• Business Quant data shows INBX's Non-Current Assets at $13.6 million in Q4 2025, $16.0 million in Q3 2025, and $18.2 million in Q2 2025.